ArticleHealthcare (Basel, Switzerland)2026
Serum Tetranectin Level and Its Association with Metabolic Parameters in Women with Gestational Diabetes Mellitus: A Case-Control Study.
Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesGestational diabetes mellitus (GDM) is a heterogeneous metabolic disorder characterized by impaired glucose regulation and insulin resistance. Tetranectin is a circulating protein implicated in metabolic regulation and diabetes-related dysfunction; however, serum tetranectin levels have not previously been investigated in women with GDM. This study aimed to compare serum tetranectin levels between women with GDM and normoglycemic pregnant controls and to evaluate their associations with metabolic parameters and discriminatory performance for GDM.
methodsThis prospective case-control study included 89 pregnant women recruited at the Department of Obstetrics and Gynecology, Antalya Education and Research Hospital, between January 2023 and March 2025, comprising 45 women with GDM and 44 normoglycemic controls. GDM was diagnosed using a 75 g oral glucose tolerance test. Serum tetranectin levels were measured using a commercially available enzyme-linked immunosorbent assay. Clinical, obstetric, metabolic, and laboratory parameters were compared between groups. Correlations between serum tetranectin and metabolic parameters were assessed using Spearman's correlation analysis. Binary logistic regression was performed to evaluate the independent association between serum tetranectin and GDM. Receiver operating characteristic curve analysis was used to assess discriminatory performance.
resultsNo statistically significant differences were observed in baseline maternal and obstetric characteristics between the groups. Serum tetranectin levels were significantly higher in women with GDM than in normoglycemic controls (155.42 [147.99-181.36] ng/mL vs. 103.82 [66.89-159.76] ng/mL,
conclusionsSerum tetranectin levels were significantly elevated in women with GDM and remained independently associated with GDM status after adjustment for maternal age, gestational age at sampling, and body mass index. Serum tetranectin showed associations with several metabolic parameters; however, after multiple-testing correction, only fasting glucose and HbA1c remained significantly correlated with TN. Although its discriminatory performance was moderate, serum tetranectin may represent a biologically plausible circulating biomarker associated with the metabolic environment of GDM. Larger longitudinal studies are needed to validate these findings and clarify the mechanistic role of tetranectin in GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.